Liver Disease
From the Journals
HBV: Surface antigen titer and ALT predict seroconversion
In patients with hepatitis B virus infection, surface antigen titer and alanine aminotransferase level may independently predict spontaneous...
From the AGA Journals
GALAD score predicts NASH-HCC more than a year in advance
The score, which combines sex, age, alpha-fetoprotein-L3, alpha-fetoprotein, and des-gamma-carboxyprothrombin is blood based and can replace...
From the Journals
Serum keratin 18 promising as AAH biomarker
There is a stronger association between serum level of keratin 18 and amount of hepatocyte death and liver disease severity than for other...
From the Journals
Telehealth appears to help speed front end of liver transplant process
Shorter evaluation times did not translate to shorter transplantation times.
From the Journals
Liver fibrosis scores predict CV event risk associated with NAFLD
NAFLD is associated with a twofold increase in cardiovascular events, and liver fibrosis in NAFLD is associated with a fourfold increase.
From the Journals
Long-term entecavir looks safe, effective in HBV
The entecavir and nonentecavir trial arms did not significantly differ in time-to-event analyses of malignant neoplasms, liver-related HBV disease...
From the AGA Journals
Fibrosis scoring systems have ‘modest’ predictive value in general population
For predicting severe liver disease, investigators say today’s scoring systems lack precision in unselected populations with low prevalence of...
From the AGA Journals
No clear-cut evidence of vedolizumab effect in retrospective study of primary sclerosing cholangitis
Cholestasis markers dropped in some, but not all, patients with primary sclerosing cholangitis and inflammatory bowel disease, though a...
Conference Coverage
What’s new in hepatitis C: Four themes that dominated at the Liver Meeting
BOSTON – AASLD highlights included treatment of persons who inject drugs, new directions in pangenotypic therapy,...
News
AASLD debrief: Five drugs show promise in NAFLD (and two do not)
BOSTON – Promising new data for cotadutide, licogliflozin, tropifexor, saroglitazar, and PF-05221304 highlighted in...